Redirecting cytotoxic T cells with chemically programmed antibodies

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• T-cell engaging bispecific antibodies (T-biAbs) offer potent and selective cancer cell cytotoxicity.
• Chemically programmed T-biAbs (cp-T-biAbs) combine small molecules for targeting with antibodies for T-cell activation.
• Switchable chimeric antigen receptor T cells (sCAR-Ts) can also be controlled by small molecules via chemically programmed antibodies.

Purpose of the Study:

• To review the concept of chemically programmed antibodies for cancer immunotherapy.
• To highlight the potential of cp-T-biAbs and cp-sCAR-Ts in enhancing small molecule-based cancer therapy.
• To discuss the broadening utility of small molecules in cancer treatment through T-cell recruitment strategies.

Main Methods:

• Review of existing literature and concepts on chemically programmed antibodies.
• Analysis of the mechanisms of action for cp-T-biAbs and cp-sCAR-Ts.
• Conceptual framework for small molecule-driven cancer immunotherapy.

Main Results:

• Chemically programmed antibodies enable precise control over T-cell engagement in cancer therapy.
• cp-T-biAbs and cp-sCAR-Ts effectively link small molecule targeting with T-cell-mediated cytotoxicity.
• Small molecules can be endowed with the power of cancer immunotherapy through these engineered systems.

Conclusions:

• Chemically programmed antibodies represent a promising strategy for cancer immunotherapy.
• This approach broadens the therapeutic applications of small molecules in oncology.
• The combination of small molecules with T-cell engaging technologies offers a powerful new avenue for cancer treatment.